Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 14, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 26
- 0 vs. Q4 2023
- Portfolio value
- $389.9M
- +$100.8M (+34.9%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| LBRDKLiberty Broadband Corp | COM SER C | 1,886,260 | $108.0M | 27.7% | +1,701,800+922.6% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 592,528 | $29.2M | 7.5% | +35,600+6.4% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 175,672 | $26.6M | 6.8% | +11,900+7.3% | Added | History |
| ARVNArvinas, Inc. | COM | 539,100 | $22.3M | 5.7% | +34,400+6.8% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 677,100 | $21.8M | 5.6% | +60,000+9.7% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 158,457 | $20.5M | 5.3% | +13,100+9.0% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 50,000 | $19.7M | 5.0% | +50,000 | New | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 360,916 | $18.1M | 4.6% | −534,084−59.7% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 238,046 | $16.7M | 4.3% | −193,647−44.9% | Reduced | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 503,759 | $16.2M | 4.2% | +45,100+9.8% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 840,453 | $15.5M | 4.0% | +70,800+9.2% | Added | History |
| EYPTEyePoint, Inc. | COM NEW | 656,600 | $13.6M | 3.5% | +656,600 | New | History |
| DISH Network CORP25470MAF6 | NOTE 12/1 | – | $13.5M | 3.4% | – | New | – |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $12.8M | 3.3% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,649,221 | $12.7M | 3.3% | +213,900+14.9% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,490,170 | $12.4M | 3.2% | +172,300+13.1% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 402,400 | $9.97M | 2.6% | +53,100+15.2% | Added | History |
| Churchill Capital Corp VII17144M110 | *W EXP 02/29/202 | 548,000 | $175.4K | <0.1% | 00.0% | Unchanged | – |
| MNYWWMoneyHero Ltd | *W EXP 09/13/202 | 895,000 | $108.5K | <0.1% | +895,000 | New | History |
| CLDICalidi Biotherapeutics, Inc. | CL A | 125,000 | $70.6K | <0.1% | 00.0% | Unchanged | History |
| CNDAWConcord Acquisition Corp II | *W EXP 99/99/999 | 408,333 | $45.4K | <0.1% | 00.0% | Unchanged | History |
| Compass Digital Acquisitn CoG2476C123 | *W EXP 09/29/202 | 459,906 | $42.3K | <0.1% | 00.0% | Unchanged | – |
| CLDWWCalidi Biotherapeutics, Inc. | *W EXP 03/14/202 | 655,200 | $34.1K | <0.1% | 00.0% | Unchanged | History |
| Swiftmerge Acquisition CorpG63836111 | *W EXP 12/13/202 | 490,000 | $27.4K | <0.1% | 00.0% | Unchanged | – |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $25.0K | <0.1% | 00.0% | Unchanged | – |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $8.23K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q4 2023 (4)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| FOLDAmicus Therapeutics, Inc. | COM | 1,489,025 | $21.1M | 7.3% | History |
| Home Plate Acquisition Corp43734R111 | *W EXP 09/30/202 | 331,416 | $20.0M | 6.9% | – |
| MORFMorphic Holding, Inc. | COM | 496,856 | $14.3M | 5.0% | History |
| Ross Acquisition Corp IIG7641C114 | *W EXP 02/01/202 | 439,666 | $24.6K | <0.1% | – |